This Month in Process Manufacturing – February 2026 

📚 New Blog Posts

1. The Hidden Cost of Legacy Systems: How Disconnected Software Failed a Leading Specialty Chemical Manufacturer

2. The Reality of Lot Traceability in Process Manufacturing

3. KPIs That Drive Enterprise Value in $10–$50M Process Manufacturers (Part 2 of 2)

A monthly update for process manufacturing leaders across food, pharmaceutical, nutraceutical, chemical, and other industries 

🎯 EXECUTIVE BRIEF 

What Process Manufacturing Leaders Need to Know This Month 

If you operate a $5M–$50M process manufacturing business, this February 2026 edition highlights the buyer activity you’ve been waiting for. Manufacturing PMI hit 52.6%—the first expansion after 12 months of contraction—and private equity firms are deploying capital aggressively across food, pharma, chemical, nutraceutical, and personal care sectors. 

Here’s what matters for your business: Operational documentation is now driving 30-50% valuation premiums. Recent specialty adhesives deal commanded 6.2x EBITDA (6.2 times annual earnings) versus the typical 4.5x—the difference? Complete batch records, deviation tracking, and audit-ready traceability systems. 

Buyers aren’t chasing growth projections anymore. They’re paying premiums for what they can verify: repeatable processes, regulatory compliance, and integration-readiness. Whether you’re evaluating a sale in the next 12-24 months or building long-term value, operational maturity is your highest-ROI investment. 

📊 BY THE NUMBERS 

Manufacturing Expansion Returns: 

• 52.6% — ISM Manufacturing Purchasing Managers’ Index (PMI) for January 2026, first expansion in 12 months and highest since February 2022 

• 57.1% — New Orders Index surged 9.7 points, strongest reading in nearly four years 

M&A Market Momentum: 

• 79% — Pharma deal value increase, signaling decisive return of confidence 

• 47.6% — Private equity share of chemical sector deals, highest on record 

• 6.2x EBITDA — Recent specialty adhesives multiple (6.2 times annual earnings) vs. 4.5-5.0x typical range, driven by operational documentation 

Sector-Specific Signals: 

• $170B+ — Pharmaceutical patent cliff revenue at risk by 2032, driving aggressive M&A 

• 120+ metabolic assets — GLP-1 obesity market creating deep M&A pipeline across 60 companies 

• 30-50% — Valuation premium for businesses with documented operational excellence vs. those lacking process controls  

🏭 PROCESS MANUFACTURING INSIGHTS 

Pharmaceutical & Life Sciences Manufacturing 

The $170B+ patent cliff looming by 2032 drives unprecedented acquisition urgency. Key trends: 

• GLP-1 obesity market competition intensified with multiple bidding wars 

• 80%+ of recent radio pharma deals included manufacturing integration—buyers want to own capacity, not just molecules 

Buyer Focus: Late-stage clinical assets, next-generation delivery platforms, vertical integration, manufacturing capacity control. 

Chemical Manufacturing (Specialty & Coatings) 

January opened strong with key platform and add-on activity: 

• Windjammer Capital acquired MFG Chemical from Platte River Equity (January 6) 

• Riverside Company invested in Key Polymer as add-on to platform Seatex 

• Integration-ready businesses commanding 5.5-6.5x EBITDA (5.5-6.5 times annual earnings) 

• Water treatment businesses with 95%+ customer retention remain hot targets 

• BASF’s AgBiTech acquisition (H1 2026 close) creates demand for qualified mid-market contract manufacturers 

Buyer Focus: Repeatable formulations, operational discipline (>95% OTIF, <5% deviation rates), integration readiness, complete FDA/EPA documentation. 

Nutraceutical & Supplement Manufacturing 

Contract manufacturing consolidation accelerates as PE firms view CDMOs as defensive play. Key trends: 

• 41% of consumers now trust AI recommendations for supplement guidance 

• FDA proposed rule: single DSHEA disclaimer on labels (welcomed by industry) 

• Functional wellness and practitioner-sold supplements with recurring revenue attract investment 

• Precision nutrition and personalized supplement strategies gaining prominence 

Buyer Focus: Contract manufacturers with vertical integration, science-backed formulations with third-party validation, professional channel recurring revenue models. 

Food & Beverage Manufacturing 

Better-for-you products and functional beverages continue attracting buyers: 

• Manufacturing PMI strength signals improved demand outlook 

• PE focuses on platform builds and bolt-on acquisitions with operational synergies 

• Supply-chain excellence and tech-enabled operations top investment priorities 

• Value-conscious consumers driving private label M&A growth 

Buyer Focus: Brands with repeat-purchase economics, scalable margins, clean-label positioning, resilient demand fundamentals. 

Personal Care & Cosmetics Manufacturing 

Strategic buyers dominate with disciplined activity: 

• Science-led clinical skincare and founder-led indie brands commanding premium valuations 

• Hair care expected to accelerate significantly in 2026 

• Contract manufacturing (CDMO/CMO) consolidation driven by nearshoring demands 

• K-Beauty consolidation continues with cross-border deals 

Buyer Focus: Founder-led brands, science-backed formulations with clinical validation, U.S. manufacturing capabilities, digital-native brands. 

💸 NOTABLE DEALS 

Chemical Manufacturing 

1. Windjammer Capital Acquires MFG Chemical from Platte River Equity 

Deal Type: PE buyout | Vertical: Specialty water treatment & coatings | Announced: January 6, 2026 

Transaction exemplifies how repeatable formulations, flexible manufacturing, and defensible customer bases drive PE interest in mid-market specialty chemicals. MFG’s 95%+ customer retention and 98.5% OTIF delivery were critical value drivers. 

Leadership Takeaways: 

• CEOs/Owners: Customer retention metrics outweigh raw revenue growth. Build “why we win” narrative around operational reliability and relationship stickiness. 

• CFOs/Controllers: Product-level profitability and customer concentration analysis are essential diligence deliverables. Prepare a detailed margin bridge. 

• COOs: Batch record integrity and <5% deviation rate command premium multiples. Document QC consistency and delivery performance metrics. 

• CTOs/IT: Audit-ready traceability systems accelerate diligence and reduce buyer risk perception. ERP compatibility matters for integration planning. 

2. Riverside Company Invests in Key Polymer (Seatex Platform Add-On) 

Deal Type: Add-on acquisition | Vertical: Adhesives & sealants | Announced: January 2026 

Platform + add-on strategy demonstrates integration readiness, which drives deal execution. Key Polymer’s standardized processes and compatible ERP enabled rapid integration planning and premium valuation. 

Leadership Takeaways: 

• CEOs/Owners: Integration feasibility is as important as standalone value. Clean operational processes create platform buyer appeal. 

• CFOs: Product-level profitability transparency enables synergy modeling and cross-selling identification during diligence. 

• COOs: Process standardization and documentation quality impact integration timeline projections—key drivers of add-on valuations. 

• IT/Systems: ERP compatibility with platform infrastructure reduces technical integration risk and accelerates close. 

3. BASF to Acquire AgBiTech 

Deal Type: Strategic expansion | Vertical: Agricultural biologicals | Expected Close: H1 2026 

Large chemical companies expanding into biologics create immediate downstream demand for qualified contract manufacturers with regulatory-grade capabilities. Mid-market suppliers should evaluate second-source qualification opportunities. 

Leadership Takeaways: 

• CEOs: Strategic M&A by large players creates contract manufacturing opportunities. Position as a qualified second-source supplier. 

• CFOs: Long-term supply agreements with strategic buyer’s command 20-30% premium pricing for regulatory-compliant production. 

• COOs: Regulatory-grade intermediate production requires full traceability, environmental controls, FDA/EPA-compliant batch documentation. 

• Quality/Regulatory: Second-source qualification audits are extensive. Proactive compliance documentation creates a competitive advantage. 

Pharmaceutical & Life Sciences 

Merck Acquires Cidara Therapeutics 

Deal Value: ~$9.2B | Vertical: Respiratory/infectious disease | Announced: Late 2025 

Merck pivots toward respiratory pipeline expansion by acquiring Cidara’s late-stage flu antiviral candidate. Deal demonstrates pharmaceutical urgency to fill patent cliffs with near-commercial assets. 

Key Insight: Late-stage assets with clear commercial pathways for large addressable markets justify aggressive pricing. 

Nutraceutical & Supplement 

1. Market Trend: AI-Driven Supplement Discovery Accelerates 

Development: January 2026 

Consumer research shows 41% now trust AI recommendations for supplement guidance, shifting from traditional research methods. This raises stakes for accuracy, transparency, and brand education. 

Leadership Implications: Transparency around ingredient sourcing and scientific validation matters more than ever. Brands fail to substantiate claims of risk misrepresentation in AI-driven recommendations. 

2. FDA Proposes DSHEA Disclaimer Rule Change 

Regulatory Update: January 2026 

FDA proposed rule requiring only one DSHEA disclaimer on supplement labels welcomed by industry stakeholders. Change formalizes current practice but could forestall class action lawsuits. 

Implication: Regulatory streamlining creates a favorable compliance environment. Focus shifts to substantiation and transparency. 

3. FSMA Food Traceability Rule Compliance 

FSMA Food Traceability Rule compliance deadline extended to July 2028; manufacturers must prepare for end-to-end supply chain traceability and electronic recordkeeping systems. 

⚙️ WHAT BUYERS ARE REALLY PAYING FOR 

Universal Value Drivers Across All Process Manufacturing Sectors 

1. Repeatable Processes & Formulation Stability 

• Documented batch-to-batch consistency (<2% variation over 24+ months) 

• Statistical process control and multi-year stability data 

• Command 25-40% valuation premiums 

• Recent example: 6.2x EBITDA (6.2 times annual earnings) vs. 4.5-5.0x typical range 

2. Operational Discipline & Quality Excellence 

• Complete batch records (24-36 months documentation) 

• OTIF delivery >95%, deviation rates <5% 

• Documented corrective actions 

• Increases multiples by 1.0-1.5x across all verticals 

3. Integration Readiness 

• Clean data systems, standardized processes 

• Transparent operations 

• Close 20-30% faster, often receive exclusive negotiating periods 

4. Regulatory & Quality Compliance 

• Food: FDA compliance, GFSI certification, allergen control, traceability 

• Pharma: cGMP documentation, FDA inspection history, quality system maturity 

• Nutraceuticals: NSF/GMP certifications, third-party testing, substantiation data 

• Chemicals: EPA permits, TSCA compliance, EHS documentation 

• Personal Care: Cosmetic GMP, safety assessments, international compliance 

5. Customer Quality & Retention 

• Long-term relationships, retention rates >90% 

• Documented quality scorecards, low complaint rates 

• Create defensible competitive positions 

• Example: MFG Chemical’s 95%+ retention cited as critical value driver 

🎤 INDUSTRY VOICE

Operational Documentation: The 40% Valuation Premium 

A California specialty adhesives manufacturer with $18M revenue completed a competitive auction in January that revealed how operational documentation drives premium valuations. 

The company had solid margins (~45%) and steady growth (~8% CAGR). Differentiation came from comprehensive documentation: 36 months of complete batch records, detailed deviation tracking with root cause analysis, audit-ready traceability, and quality metrics showing <2% batch variation.  

During three days of on-site diligence, the buyer reviewed processes and documentation. The competing bid—a business with 20% higher revenue—couldn’t produce complete batch records for 24 months. 

“The buyer walked away from $22M in revenue because they couldn’t verify process consistency,” the owner explained. “They told us: ‘We can’t pay for revenue we can’t trust.'” 

The California manufacturer commanded 6.2x EBITDA (6.2 times annual earnings)—40% above the 4.5x segment average—and closed in 87 days vs. 120–150-day typical timeline. 

The lesson applies across all process verticals: Documented operational excellence drives 30-50% valuation premiums. Buyers reward businesses where they can verify—not just believe—that processes are repeatable, compliant, and integration-ready. 

Critical documentation that drives premium valuations: 

• 24-36 months complete batch production records (no gaps) 

• Deviation logs with root cause analysis, corrective actions, CAPA closure 

• Quality control data showing batch-to-batch consistency 

• Customer quality scorecards, complaint logs, resolution tracking 

• Environmental permits, safety certifications, training records, audit history 

• Traceability from raw material receipt through finished goods shipment 

• Maintenance logs, equipment calibration records, preventive maintenance schedules 

Timeline: 18-24 months of consistent execution to create the track record buyers value most. Start now considering M&A in 12-24 months. 

🔧 LEADERSHIP PLAYBOOK 

What Leadership Should Focus on Now 

For Finance Leaders (CFOs/Controllers) 

• Build comprehensive margin bridge: product-level profitability, customer contribution, COGS drivers 

• Document customer concentration: retention metrics, churn analysis, lifetime value 

• Track KPIs: EBITDA margin trends, working capital efficiency, cash conversion cycle 

• Prepare normalized financial statements with documented add-backs 

For Operations Leaders (COOs/VP Operations) 

• Audit batch records: ensure 24-36 months complete documentation with no gaps 

• Review deviation management: root cause analysis, CAPA closure, trend analysis 

• Optimize OTIF delivery: target >95% with weekly tracking 

• Document processes: SOPs, process flows, control points, training records 

• Implement statistical process control showing batch-to-batch consistency 

For Technology & IT Leaders (CTOs/CIOs) 

• Ensure traceability systems provide audit-ready reports from raw materials through finished goods 

• Verify formulation control: version control, change management, access security 

• Document system architecture, data dictionaries, integration points 

• Review cybersecurity: network security, backup/recovery, disaster recovery plans 

For R&D, Quality & Regulatory Leaders 

• Food: Document formulations, allergen controls, nutritional claims, shelf-life studies 

• Pharma: Maintain drug master files, method validation, stability programs, tech transfer 

• Nutraceuticals: Third-party testing, COA archives, supplier qualifications 

• Chemicals: Formulation IP protection, safety data sheets, regulatory compliance 

• Personal Care: Safety assessments, stability studies, preservative efficacy, claim substantiation 

• Maintain current registrations, licenses, permits with documented renewal dates 

• Document regulatory inspection history, responses, CAPA closure evidence 

Focus: Start now if you consider M&A in 12-24 months. Building operational documentation takes 18-24 months of consistent execution. 

📜 POLICY & COMPLIANCE  

Federal Regulatory Activity 

FDA: 

• Pre Check Program streamlines pharma oversight (increases documentation requirements) 

• Advanced manufacturing guidance finalized 

• Remote regulatory assessment guidance released 

• FSMA emphasis on preventive controls and traceability continues 

• DSHEA disclaimer rule proposed (single label disclaimer) 

EPA: 

• PFAS reporting rule imposes detailed requirements (even for unintentional presence) 

• TSCA updates ongoing 

• Emission compliance scrutiny increasing 

Administration Developments: 

• Most Favored Nations pricing policy affecting pharma dealmaking 

• UK agreed to 25% drug price increases for 3-year tariff-free exports 

• U.S. manufacturing investments exempt from additional tariffs 

Sector-Specific Compliance 

• Pharmaceuticals: Manufacturing capacity control becoming strategic priority; vertical integration accelerating 

• Nutraceuticals: AI-driven discovery raising stakes for transparency; third-party certification now competitive requirement 

• Chemicals: TSCA risk evaluations continuing; ag/biologicals expansion creating demand for regulatory-grade production 

• Food & Beverage: FSMA Food Traceability Rule compliance deadline extended to July 2028; manufacturers must prepare for end-to-end supply chain traceability and electronic recordkeeping systems 

Implication: Buyers discount incomplete regulatory documentation by 15-25%; proactive compliance drives premium valuations 

💡 ONE-MINUTE EXECUTIVE TALKING POINTS 

1. Manufacturing rebound: ISM PMI 52.6% (first expansion in 12 months), New Orders 57.1%, capacity 82.4% 

2. Pharma M&A surge: 79% deal value increase—decisive confidence return 

3. Patent cliff urgency: $170B+ pharma revenue at risk by 2032; 120+ GLP-1 assets create deep pipeline 

4. Operational documentation premium: 30-50% valuation advantage—example: 6.2x EBITDA (6.2 times annual earnings) vs. 4.5x 

5. Chemical momentum: Windjammer/MFG and Riverside/Key Polymer demonstrate platform + add-on strength 

6. Vertical integration focus: Pharma buyers want manufacturing capacity, not just molecules—80%+ of deals included manufacturing 

7. Nutra AI shift: 41% trust AI for supplement guidance—raises transparency stakes 

8. Compliance = value: Incomplete documentation creates 15-25% discounts 

9. Timeline critical: 18-24 months needed to build documentation track record 

10. Cross-sector lesson: Operational maturity beats growth projections in 2026 M&A market 

📚 SOURCES & REFERENCES  

Economic & Manufacturing Data: 

• ISM Manufacturing PMI Report – January 2026 

• 2025 Fourth Quarter Manufacturers’ Outlook Survey

• U.S. Federal Reserve – Industrial Production 

M&A & Industry Intelligence: 

• CNBC – Big Pharma Patent Cliff ($170B+) 

• Pharmaceutical Technology – Biopharma 2025 M&A Boom 

• HealthEconomics.com – Patent Cliffs Drive 2025 M&A 

• RD WorldOnline – Life Sciences M&A Hit $240B 

• Fierce Pharma – 2026 M&A Forecast 

• Pharma Salmanac – How Pharma M&A Evolved in 2025 

• DeepCeutix – $300B Revenue Loses Patent Protection 

• Manufacturing Dive – PMI Expands in January 

• Shutdown Deal Restricts Funds for FSMA 204, Produce Safety Rule Enforcement  

Regulatory & Compliance: 

• U.S. FDA – Newsroom 

• U.S. EPA – Newsreleases 

• American Chemistry Council 

• American Herbal Products Association 

Nutraceutical & Supplement Intelligence: 

• New Hope Network 

• Nutritional Outlook 

• SPINS 

• DataM Intelligence 

Industry Associations: 

• SOCMA (Society of Chemical Manufacturers & Affiliates) 

• AIChE (American Institute of Chemical Engineers) 

• Natural Products Association 

• Personal Care Products Council 

This Month in Process Manufacturing is published monthly by BatchMaster Software. It provides process manufacturing leaders with curated insights on M&A activity, regulatory trends, and operational best practices across food, pharmaceutical, nutraceutical, chemical, and personal care industries.